Ketamine produces a wide range of effects depending on the dose, how it’s taken, and whether it’s used once or repeatedly. At low doses, it alters perception, elevates mood, and raises heart rate and blood pressure. At higher doses, it causes full dissociation from your body and surroundings. Repeated use over time can damage the bladder, impair memory, and lead to dependence.
How Ketamine Works in the Brain
Ketamine blocks a specific type of receptor in the brain that normally responds to glutamate, the main chemical signal that excites nerve cells. It doesn’t simply shut this receptor down. Instead, it waits for the receptor’s channel to open, then slips inside and physically blocks the flow of ions through it. It can even stay lodged in the channel after it closes, which is why its effects linger beyond what you’d expect from a fast-acting drug.
This blockade sets off a chain reaction. By preferentially silencing certain inhibitory brain cells, ketamine actually increases overall glutamate release in the prefrontal cortex and hippocampus. That surge of glutamate activates a different set of receptors, which in turn triggers the growth of new connections between neurons. This burst of new wiring, particularly through a growth-promoting protein called BDNF, is what researchers believe drives ketamine’s rapid antidepressant effects.
Immediate Physical Effects
Ketamine stimulates the sympathetic nervous system, the same system that activates during a fight-or-flight response. This means mild to moderate increases in blood pressure, heart rate, and cardiac output that are typically short-lived. In one study of adults receiving ketamine for sedation, 29% had a clinically significant spike in vital signs (defined as 20% or more above baseline) immediately after the dose, and 71% experienced one at some point during the procedure.
When given intravenously at anesthetic doses, ketamine takes effect within 10 to 30 seconds and produces dissociation lasting roughly 5 to 15 minutes. Other common physical effects include nausea, dizziness, increased salivation, and a sensation of heaviness or numbness in the limbs. At sub-anesthetic doses used in clinical settings, these effects are milder but still noticeable.
Psychological and Perceptual Effects
Ketamine doesn’t typically cause true hallucinations. In a controlled study of healthy volunteers published in the British Journal of Psychiatry, not a single participant experienced visual or auditory hallucinations. What ketamine does produce is a rich set of perceptual distortions: colors appearing brighter or blurred together, objects losing their sharp edges, surfaces feeling “more liquid,” and a sense that your body has changed size or shape. One participant described their hands looking small with impossibly long fingers. Another said their legs appeared to belong to someone else.
Changes in time perception were among the most common effects, reported by 11 of the volunteers. Heightened sensitivity to sound was also frequent. Some people described feelings resembling depersonalization (feeling detached from yourself) or derealization (feeling like the world isn’t real), though researchers noted these clinical terms didn’t fully capture what participants actually experienced. Descriptions like “I feel like I’m shrunken inside” or “each limb seems separate, detached from each other” were more typical than the textbook version of those symptoms.
Antidepressant and Pain Relief Effects
Ketamine’s most notable therapeutic effect is its speed as an antidepressant. Traditional antidepressants take weeks to work. Ketamine can produce measurable mood improvement within hours. In a randomized trial of hospitalized patients with depression, 46.9% of those receiving ketamine infusions responded to treatment, and 43.8% achieved full remission. These are significant numbers for treatment-resistant depression, where patients have already failed multiple other medications.
The FDA has approved a nasal spray containing esketamine (a close molecular relative) specifically for treatment-resistant depression and for depressive symptoms with acute suicidal thoughts, though it must be used alongside an oral antidepressant. Ketamine itself remains FDA-approved only as an anesthetic. Its use for depression, anxiety, PTSD, and other psychiatric conditions is off-label, and the FDA has warned that compounded ketamine products marketed for psychiatric use have not been evaluated for safety or effectiveness.
For chronic pain, ketamine shows particular promise in conditions that resist standard painkillers. In a review of sickle cell crisis cases, 83.3% of 18 patients experienced significant pain improvement and reduced opioid use with sub-anesthetic ketamine. Patients with complex regional pain syndrome and neuropathic pain have also benefited. One randomized trial found that oral ketamine taken three times daily provided greater pain relief after three months than other treatment groups.
Bladder Damage From Repeated Use
One of the most serious long-term consequences of regular ketamine use is severe bladder damage. First documented in 2007, ketamine-induced cystitis involves chronic inflammation that causes pelvic pain, an urgent and constant need to urinate, painful urination, and blood in the urine. Around 20% of frequent ketamine users report these symptoms, compared to about 7% of infrequent users. Regular use increases the risk of cystitis symptoms by three to four times.
The damage isn’t limited to the bladder lining. Prolonged use can cause the bladder wall to stiffen with scar tissue, reducing its capacity to store urine. It can also affect the upper urinary tract, leading to urine backing up into the kidneys and, in severe cases, kidney failure. In one documented case, a 25-year-old with a long history of ketamine use eventually needed surgical removal of his bladder after less invasive treatments failed. Perhaps most striking, a 26-year-old man who had used ketamine daily only as a teenager, between ages 15 and 17, still presented with painful urination, incontinence, and blood in his urine nine years after stopping. The damage, once done, can persist long after the drug is gone.
Cognitive Effects of Long-Term Use
Chronic ketamine users consistently perform worse than non-users on tests of intelligence, memory, and executive function. The deficits span multiple types of memory: working memory (holding information in mind while using it), spatial memory (navigating and recalling locations), and episodic memory (remembering personal experiences). Brain imaging studies show these impairments line up with measurable changes in brain structure and function, including shrinkage in the hippocampus and prefrontal cortex, regions critical for memory and decision-making.
The brain appears to try compensating. Chronic users show increased activity in certain receptors in the prefrontal cortex, likely an attempt to make up for deficient signaling in that area. But this compensatory mechanism doesn’t fully restore normal function, and users continue to show impaired performance on cognitive tasks.
Dependence and Withdrawal
Ketamine can produce psychological dependence with regular use, and abrupt cessation after extended use carries real withdrawal symptoms. These include anxiety, sweating, drowsiness, and notably, heightened pain sensitivity. In one documented case, a patient developed extreme sensitivity to touch across her entire body within 12 hours of stopping ketamine. Moderate to severe startle responses to being touched and prolonged agitation lasting several minutes have also been reported.
Toxicity and Overdose Risk
Ketamine has a relatively wide safety margin compared to many other recreational drugs. Based on animal studies, researchers estimated the median lethal intravenous dose for a 70-kilogram human at roughly 678 mg, giving it a safety ratio of about 25 (meaning the lethal dose is approximately 25 times a typical recreational dose). That said, human toxicity data remains limited, and the risk rises substantially when ketamine is combined with alcohol, opioids, or sedatives, all of which compound its effects on breathing and consciousness. Ketamine is classified as a Schedule III controlled substance, reflecting its recognized potential for abuse alongside its legitimate medical uses.